TRML — Tourmaline Bio Cashflow Statement
0.000.00%
- $329.81m
- $36.76m
- 55
- 42
- 14
- 30
Annual cashflow statement for Tourmaline Bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -18.2 | -22.7 | -47.8 | -73.9 | -42.1 |
Depreciation | |||||
Non-Cash Items | 0.201 | 1.43 | 4.91 | 10.6 | 14.2 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -0.085 | 1.61 | 2.31 | 1.1 | -0.168 |
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -17.7 | -19.2 | -40 | -60.9 | -28.1 |
Capital Expenditures | -0.562 | -1.29 | -2.44 | -3.04 | -0.056 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | 0 | -132 | -94 | 58.7 | 3.9 |
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -0.562 | -133 | -96.4 | 55.7 | 3.84 |
Financing Cash Flow Items | — | — | -0.277 | 0 | 64.8 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 36.2 | 131 | 137 | 0.242 | 157 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 18 | -21.4 | 1.02 | -4.94 | 132 |